See more : Capri Global Capital Limited (CGCL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Polyphor AG (POLN.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polyphor AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Stockmann Oyj Abp (STOCKA.HE) Income Statement Analysis – Financial Results
- Central Bancompany, Inc. (CBCYB) Income Statement Analysis – Financial Results
- Ashoka Refineries Limited (ASHOKRE.BO) Income Statement Analysis – Financial Results
- Henan Jindan Lactic Acid Technology Co., Ltd (300829.SZ) Income Statement Analysis – Financial Results
- Rathi Bars Limited (RATHIBAR.BO) Income Statement Analysis – Financial Results
Polyphor AG (POLN.SW)
About Polyphor AG
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.28M | 10.04K | 6.55M | 4.30M | 8.65M | 7.67M | 9.82M | 39.86M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | -634.02K | -1.69M | -40.16K | 978.48K | 589.36K |
| Gross Profit | 14.28M | 10.04K | 6.55M | 4.93M | 10.34M | 7.71M | 8.84M | 39.27M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 114.75% | 119.55% | 100.52% | 90.04% | 98.52% |
| Research & Development | 52.34M | 60.74M | 44.77M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.57M | 4.66M | 2.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 771.13K | 1.44M | 930.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.34M | 6.10M | 3.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -963.57K | 0.00 | 0.00 | 43.68M | 34.26M | 42.93M | 36.74M | 29.22M |
| Operating Expenses | 56.72M | 66.84M | 48.39M | 43.68M | 34.26M | 42.93M | 36.74M | 29.22M |
| Cost & Expenses | 56.72M | 66.84M | 48.39M | 43.05M | 32.57M | 42.89M | 37.72M | 29.81M |
| Interest Income | 52.27K | 1.32M | 284.68K | 30.73K | 27.38K | 44.37K | 9.26K | 599.00 |
| Interest Expense | 294.34K | 630.05K | 4.29M | 446.43K | 226.00K | 255.56K | 278.26K | 331.79K |
| Depreciation & Amortization | 2.10M | 2.31M | 1.89M | 8.83M | 2.81M | 2.70M | 2.39M | 2.14M |
| EBITDA | -42.56M | -61.73M | -44.74M | -29.82M | -21.10M | -32.12M | -25.58M | 12.17M |
| EBITDA Ratio | -298.08% | -614,835.56% | -683.47% | -693.61% | -243.94% | -418.68% | -260.46% | 30.52% |
| Operating Income | -44.65M | -64.04M | -46.63M | -38.65M | -23.91M | -34.82M | -27.97M | 10.02M |
| Operating Income Ratio | -312.76% | -637,861.18% | -712.35% | -899.03% | -276.41% | -453.88% | -284.79% | 25.15% |
| Total Other Income/Expenses | -294.34K | -630.05K | 799.80K | -446.42K | -226.00K | -255.56K | -278.26K | -331.79K |
| Income Before Tax | -44.95M | -64.67M | -45.83M | -39.10M | -24.14M | -35.08M | -28.24M | 9.69M |
| Income Before Tax Ratio | -314.82% | -644,136.53% | -700.13% | -909.41% | -279.02% | -457.21% | -287.63% | 24.31% |
| Income Tax Expense | 294.34K | 630.05K | 4.29M | 446.43K | 226.00K | 255.56K | 278.26K | 331.79K |
| Net Income | -45.24M | -65.30M | -50.12M | -39.54M | -24.36M | -35.34M | -28.52M | 9.36M |
| Net Income Ratio | -316.88% | -650,411.89% | -765.71% | -919.80% | -281.64% | -460.54% | -290.46% | 23.48% |
| EPS | -4.07 | -5.91 | -5.35 | -3.67 | -3.94 | -5.71 | -4.61 | 1.51 |
| EPS Diluted | -4.07 | -5.91 | -5.35 | -3.67 | -2.26 | -3.28 | -2.65 | 0.87 |
| Weighted Avg Shares Out | 11.11M | 11.05M | 9.36M | 10.78M | 6.19M | 6.19M | 6.19M | 6.19M |
| Weighted Avg Shares Out (Dil) | 11.11M | 11.05M | 9.36M | 10.78M | 10.78M | 10.78M | 10.78M | 10.78M |
Source: https://incomestatements.info
Category: Stock Reports